|
Strain Name
|
C57BL/6-Havcr2tm1(HAVCR2)Bcgen/Bcgen
|
Common Name
|
B-hTIM3 mice
|
|
Background
|
C57BL/6
|
Catalog number
|
110018
|
Related Genes
|
HAVCR2 (hepatitis A virus cellular receptor 2)
|
NCBI Gene ID
|
171285
|
mRNA expression analysis
Strain specific analysis of TIM3 gene expression in WT and hTIM3 mice by RT-PCR. Mouse Tim3 mRNA was detectable in splenocytes of wild-type (+/+) mice. Human TIM3 mRNA was detectable only in H/H but not in +/+ mice.
Protein expression analysis
Strain specific TIM3 expression analysis in homozygous B-hTIM3 mice by flow cytometry. Cells in ascites were collected from WT and homozygous B-hTIM3 (H/H) mice stimulated with anti-CD3ε in vivo, and analyzed by flow cytometry with species-specific anti-TIM3 antibody. Mouse Tim3 was exclusively detectable in non-T and non-B cells from WT mice. Human TIM3 was exclusively detectable in non-T and non-B cells from homozygous B-hTIM3 but not WT mice.
Protein expression analysis
Strain specific TIM3 expression analysis in homozygous B-hTIM3 mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hTIM3 (H/H) mice stimulated with anti-CD3ε in vivo, and analyzed by flow cytometry with species-specific anti-TIM3 antibody. Mouse Tim3 was exclusively detectable in WT mice. Human TIM3 were exclusively detectable in homozygous B-hTIM3 but not WT mice.
In vivo efficacy of anti-human TIM3 antibodies
Antitumor activity of anti-human TIM3 antibodies in B-hTIM3 mice. (A) Anti-human TIM3 antibodies inhibited MC38 tumor growth in B-hTIM3 mice. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hTIM3 mice (male, 7 week-old, n=5). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with anti-human TIM3 antibody with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, anti-human TIM3 antibody was efficacious in controlling tumor growth in B-hTIM3 mice, demonstrating that the B-hTIM3 mice provide a powerful preclinical model for in vivo evaluation of anti-human TIM3 antibodies. Values are expressed as mean ± SEM.
In vivo efficacy of anti-human TIM3 antibodies
Antitumor activity of anti-human TIM3 antibodies in B-hTIM3 mice. (A) Anti-human TIM3 antibodies inhibited MC38 tumor growth in B-hTIM3 mice. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hTIM3 mice (female, 4 week-old, n=5). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with two anti-human TIM3 antibodies with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, anti-human TIM3 Ab2 was efficacious in controlling tumor growth in B-hTIM3 mice, demonstrating that the B-hTIM3 mice provide a powerful preclinical model for in vivo evaluation of anti-human TIM3 antibodies. Values are expressed as mean ± SEM
